正在加载视频...

视频加载失败

SEC filings should be standard evidence in every drug-pricing conversation. Rob Burgess argues policymakers should compare pharma’s public promises with the legally binding disclosures made to investors—before declaring a deal finished.

168,411 次观看 • 2 个月前 •via X (Twitter)

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频